Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: Results of a phase I randomized, placebo-controlled trial

Arthritis Research and Therapy

Volumn 14, Issue 1, 2012, Pages

  Emu, Brinda ^a   Luca, Diana ^a   Offutt, Carolyn ^a   Grogan, Jane L ^a   Rojkovich, Bernadette ^b   Williams, Marna B ^a   Tang, Meina T ^a   Xiao, Jim ^a   Lee, June H ^c   Davis, John C ^a  

^a GENENTECH INC   (United States)

^b Polyclinic of the Hospital Brothers of St John of God in Budapest ^*  (Hungary)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CXCL13 CHEMOKINE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; LYMPHOTOXIN; METHOTREXATE; PATECLIZUMAB; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; T LYMPHOCYTE; VOMITING; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; HEADACHE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; CHEMOKINE CXCL13; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LYMPHOTOXIN-ALPHA; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855446791     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3554     Document Type: Article

References (22)

1. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010, 11:180-210.
2. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285. 10.1001/jama.295.19.2275, 16705109.
3. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
4. Gramaglia I, Mauri DN, Miner KT, Ware CF, Croft M. Lymphotoxin αβ is expressed on recently activated naive and Th1-like CD4 cells but is down-regulated by IL-4 during Th2 differentiation. J Immunol 1999, 162:1333-1338.
5. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005, 23:787-819. 10.1146/annurev.immunol.23.021704.115719, 15771586.
6. Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, Gribling P, Shu J, Lee WP, Refino CJ, Balazs M, Paler-Martinez A, Nguyen A, Young J, Barck KH, Carano RA, Ferrando R, Diehl L, Chatterjea D, Grogan JL. Targeted depletion of lymphotoxin-α-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009, 15:766-773. 10.1038/nm.1984, 19561618.
7. Browning JL. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev 2008, 223:202-220. 10.1111/j.1600-065X.2008.00633.x, 18613838.
8. Timmer TC, Baltus B, Vondenhoff M, Huizinga TW, Tak PP, Verweij CL, Mebius RE, van der Pouw Kraan TC. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum 2007, 56:2492-2502. 10.1002/art.22748, 17665400.
9. Weyand CM, Seyler TM, Goronzy JJ. B cells in rheumatoid synovitis. Arthritis Res Ther 2005, 7(Suppl 3):S9-S12. 10.1186/ar1737, 2833971, 15960820.
10. Young J, Yu X, Wolslegel K, Nguyen A, Kung C, Chiang E, Kolumam G, Wei N, Wong WL, DeForge L, Townsend MJ, Grogan JL. Lymphotoxin-αβ heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 2010, 51:78-86. 10.1016/j.cyto.2010.03.003, 20356761.
11. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, Goronzy JJ, Weyand CM. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001, 167:1072-1080.
12. Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 2003, 3:642-655. 10.1038/nri1151, 12974479.
13. Weyand CM. Immunopathologic aspects of rheumatoid arthritis: who is the conductor and who plays the immunologic instrument?. J Rheumatol Suppl 2007, 79:9-14.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
15. Wang H, Cain G, Kaiser R, McBride J, Lutman J, Grogan J, Gelzleichter T, Iyer S. Evaluation of a humanized monoclonal antibody targeting lymphotoxin a in non-human primates. Ann Rheum Dis 2010, 69:181. 10.1136/ard.2008.101857, 19176545.
16. Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE, Yoshikawa H, Ochi T. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 2001, 166:650-655.
17. Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:603-610.
18. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008, 58:2257-2267. 10.1002/art.23667, 18668547.
19. Meeuwisse CM, van der Linden MP, Rullmann TA, Allaart CF, Nelissen R, Huizinga TW, Garritsen A, Toes RE, van Schaik R, van der Helm-van Mil AH. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum 2011, 63:1265-1273. 10.1002/art.30273, 21305530.
20. Genovese MC, Greenwald MW, Alloway JA, Baldassare AR, Chase W, Newman C, Weaver ML. Efficacy and safety of Baminercept in the treatment of rheumatoid arthritis (RA): results of the phase 2B study in the TNF-IR population [abstract]. Arthritis Rheum 2009, 60(Suppl 10):417.
21. Isaacs JD, Genovese MC, Emery P, Scheinberg MA, Spindler AJ, Newman C, Weaver ML. Efficacy and safety of Baminercept in the treatment of rheumatoid arthritis (RA): preliminary results of the phase 2B study in the DMARD-IR population [abstract]. Arthritis Rheum 2009, 60(Suppl 10):416.
22. Grogan JL. Novel mechanism of action for anti-lymphotoxin-α in autoimmune disease: depletion of Th1 and Th17 cells [abstract]. Advances in TNF Family Research (Advances in Experimental Medicine and Biology), Proceedings of the 12th International TNF Conference, 2009 2011, 723. New York: Springer, Wallach D, Kovalenko A, Feldmann M.